HALOPERIDOL vs placebo
Death: Suicide and natural causes (no data) · patients with schizophrenia
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Findings
What do systematic reviews say?
13 questions · 13 findings · 2 reviews · Schizophrenia
No studies found 1 · 7.7%GRADE not reported 2 · 15.4%Very low 5 · 38.5%Low 2 · 15.4%Moderate 3 · 23.1%High 0 · 0%
HALOPERIDOL vs placebo
Global state: no overall improvement (psychiatrist ‐ rated) · patients with schizophrenia
HALOPERIDOL probably leads to lower overall improvement: No marked global improvement Rated by clinician compared with PLACEBO (moderate certainty).
1 finding from 1 review
- RR 0.67 [0.58, 0.78]8 studies · 307 participantsModerate
HALOPERIDOL vs placebo
Not discharged from hospital · patients with schizophrenia
It is very uncertain whether HALOPERIDOL changes not discharged from hospital compared with PLACEBO (very low certainty).
1 finding from 1 review
- RR 0.85 [0.47, 1.52]1 study · 33 participantsVery low
HALOPERIDOL vs placebo
Relapse · patients with schizophrenia
It is very uncertain whether HALOPERIDOL changes relapse compared with PLACEBO (very low certainty).
1 finding from 1 review
- RR 0.69 [0.55, 0.86]2 studies · 70 participantsVery low
HALOPERIDOL vs placebo
Leaving the study early · patients with schizophrenia
HALOPERIDOL showed no clear difference in leaving the study early compared with PLACEBO (moderate certainty).
1 finding from 1 review
- RR 0.54 [0.29, 1]8 studies · 304 participantsModerate
HALOPERIDOL vs placebo
Satisfaction with treatment · patients with schizophrenia
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
HALOPERIDOL vs placebo
Adverse effects. Specific: movement disorders ‐ parkinsonism · patients with schizophrenia
HALOPERIDOL probably leads to higher adverse effects: Movement disorders ‐ parkinsonism compared with PLACEBO (moderate certainty).
1 finding from 1 review
- RR 5.48 [2.68, 11.22]5 studies · 485 participantsModerate
HALOPERIDOL vs PLACEBO/NIL
Tranquilisation or asleep not asleep at 2 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes tranquillisation or asleep not asleep at 2 hours compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
- Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes onlyRR 0.88 [0.82, 0.95]2 studies · 220 participantsVery low
HALOPERIDOL vs PLACEBO/NIL
Repeated need for tranquillisation ‐ needing additional injections during 24 hours · patients with psychosis‐induced aggression or agitation
HALOPERIDOL may leads to lower repeated need for tranquillisation needing additional injection… compared with PLACEBO/NIL (low certainty).
1 finding from 1 review
- Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes onlyRR 0.51 [0.42, 0.62]4 studies · 660 participantsLow
HALOPERIDOL vs PLACEBO/NIL
Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · patients with psychosis‐induced aggression or agitation
1 finding from 1 review
- Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 474 participantsVery low
HALOPERIDOL vs PLACEBO/NIL
Global outcome ‐ overall improvement (not any improvement) · patients with psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in global outcome ‐ overall improvement (not any improvement) compared with PLACEBO/NIL (low certainty).
1 finding from 1 review
- Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes onlyRR 0.28 [0.08, 1.07]1 study · 40 participantsLow
HALOPERIDOL vs PLACEBO/NIL
Adverse effects: Specific ‐ dystonia during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia within 24 hours compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
- Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes onlyRR 7.49 [0.93, 60.21]2 studies · 207 participantsVery low
HALOPERIDOL vs PLACEBO/NIL
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
- Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found